Flerie
Flerie AB (publ) is a venture capital firm specializing in early-stage investments. The firm seeks to invest in life science, biotech and pharma companies engaged in drug development and associated tools or applications tackling major medical challenges of our time. The firm seeks to invest in Europe, Nordic, United States and Israel. Flerie AB (publ) was founded in 2011 and is based in Stockholm… Read more
Flerie (FLERIE) - Net Assets
Latest net assets as of December 2025: Skr3.38 Billion SEK
Based on the latest financial reports, Flerie (FLERIE) has net assets worth Skr3.38 Billion SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr3.40 Billion) and total liabilities (Skr20.30 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr3.38 Billion |
| % of Total Assets | 99.4% |
| Annual Growth Rate | 38.73% |
| 5-Year Change | 678.02% |
| 10-Year Change | N/A |
| Growth Volatility | 555.79 |
Flerie - Net Assets Trend (2016–2025)
This chart illustrates how Flerie's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Flerie (2016–2025)
The table below shows the annual net assets of Flerie from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr3.38 Billion | -19.56% |
| 2024-12-31 | Skr4.20 Billion | +1657.33% |
| 2023-12-31 | Skr238.88 Million | -28.47% |
| 2022-12-31 | Skr333.96 Million | -23.06% |
| 2021-12-31 | Skr434.04 Million | +779.90% |
| 2020-12-31 | Skr49.33 Million | -53.68% |
| 2019-12-31 | Skr106.50 Million | +65.14% |
| 2018-12-31 | Skr64.49 Million | -38.43% |
| 2017-12-31 | Skr104.75 Million | -40.98% |
| 2016-12-31 | Skr177.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Flerie's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 239830000000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr154.90 Million | 4.59% |
| Other Components | Skr5.62 Billion | 166.43% |
| Total Equity | Skr3.38 Billion | 100.00% |
Flerie Competitors by Market Cap
The table below lists competitors of Flerie ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
AstroNova Inc
NASDAQ:ALOT
|
$46.68 Million |
|
QSYS
ST:QSYS
|
$46.70 Million |
|
Coeptis Therapeutics Inc
NASDAQ:COEP
|
$46.70 Million |
|
Tin Nghia Industrial Park Development JSC
VN:TIP
|
$46.70 Million |
|
E&P Financial Group Ltd
AU:EP1
|
$46.64 Million |
|
SAMSE S.A.
LSE:0GLY
|
$46.61 Million |
|
Abliva AB
ST:ABLI
|
$46.60 Million |
|
Citizens Holding Company
NASDAQ:CIZN
|
$46.60 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Flerie's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 4,198,000,000 to 3,376,900,000, a change of -821,100,000 (-19.6%).
- Net loss of 756,900,000 reduced equity.
- Other factors decreased equity by 64,200,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-756.90 Million | -22.41% |
| Other Changes | Skr-64.20 Million | -1.9% |
| Total Change | Skr- | -19.56% |
Book Value vs Market Value Analysis
This analysis compares Flerie's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.81x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 3.30x to 0.81x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr10.64 | Skr35.10 | x |
| 2017-12-31 | Skr6.28 | Skr35.10 | x |
| 2018-12-31 | Skr3.80 | Skr35.10 | x |
| 2019-12-31 | Skr5.41 | Skr35.10 | x |
| 2020-12-31 | Skr2.08 | Skr35.10 | x |
| 2021-12-31 | Skr8.98 | Skr35.10 | x |
| 2022-12-31 | Skr6.27 | Skr35.10 | x |
| 2023-12-31 | Skr4.48 | Skr35.10 | x |
| 2024-12-31 | Skr59.57 | Skr35.10 | x |
| 2025-12-31 | Skr43.32 | Skr35.10 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Flerie utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -22.41%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -8601.14%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.01x
- Recent ROE (-22.41%) is above the historical average (-54.04%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -23.26% | -23451.70% | 0.00x | 1.10x | Skr-59.02 Million |
| 2017 | -69.46% | -64388.50% | 0.00x | 1.21x | Skr-83.23 Million |
| 2018 | -127.38% | -64178.13% | 0.00x | 1.34x | Skr-88.60 Million |
| 2019 | -82.41% | -99742.05% | 0.00x | 1.21x | Skr-98.42 Million |
| 2020 | -116.40% | -164051.43% | 0.00x | 1.24x | Skr-62.35 Million |
| 2021 | -23.74% | 0.00% | 0.00x | 1.03x | Skr-146.45 Million |
| 2022 | -30.04% | 0.00% | 0.00x | 1.05x | Skr-133.73 Million |
| 2023 | -39.88% | -97.70% | 0.33x | 1.25x | Skr-119.15 Million |
| 2024 | -5.43% | -228000.00% | 0.00x | 1.01x | Skr-647.80 Million |
| 2025 | -22.41% | -8601.14% | 0.00x | 1.01x | Skr-1.09 Billion |
Industry Comparison
This section compares Flerie's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $106,934,177
- Average return on equity (ROE) among peers: -113.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Flerie (FLERIE) | Skr3.38 Billion | -23.26% | 0.01x | $46.64 Million |
| 2cureX AB (2CUREX) | $43.03 Million | -69.18% | 0.11x | $1.39 Million |
| Abliva AB (ABLI) | $70.72 Million | -135.06% | 0.24x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $74.33 Million | -147.03% | 0.17x | $25.35 Million |
| AcouSort AB (ACOU) | $33.02 Million | -37.49% | 0.11x | $4.79 Million |
| Active Biotech AB (ACTI) | $646.03 Million | 0.00% | 0.35x | $3.42 Million |
| Alzinova AB (ALZ) | $59.11 Million | -10.49% | 0.07x | $3.99 Million |
| AlzeCure Pharma (ALZCUR) | $32.97 Million | -235.89% | 0.38x | $12.21 Million |
| Annexin Pharmaceuticals AB (ANNX) | $18.81 Million | -234.16% | 0.42x | $4.76 Million |
| Alligator Bioscience AB (ATORX) | $68.52 Million | -112.06% | 0.43x | $757.29K |
| Biosergen AS (BIOSGN) | $22.79 Million | -149.37% | 0.48x | $2.84 Million |